scholarly journals Overcoming drug delivery barriers and challenges in topical therapy of atopic dermatitis: A nanotechnological perspective

2022 ◽  
Vol 147 ◽  
pp. 112633
Author(s):  
Chetna Hemrajani ◽  
Poonam Negi ◽  
Arun Parashar ◽  
Gaurav Gupta ◽  
Niraj Kumar Jha ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Atopic Dermatitis ◽  
Topical Therapy ◽  
Barriers And Challenges

Topical Lipid Based Drug Delivery Systems for Skin Diseases: A Review

2020 ◽  
Vol 15 (4) ◽  
pp. 283-298
Author(s):  
Suresh Kumar Sahu ◽  
Rakesh Raj ◽  
Pooja Mongia Raj ◽  
Ram Alpana
Keyword(s):  
Drug Delivery ◽  
Skin Diseases ◽  
Topical Therapy ◽  
Skin Layer ◽  
Dosage Forms ◽  
Delivery Systems ◽  
Systemic Side Effects ◽  
Transcutaneous Delivery ◽  
Topical Dosage ◽  
Topical Dosage Forms

Treatment of skin ailments through systemic administration is limited due to toxicity and patients discomfort. Hence, lower risk of systemic side effects from topical dosage forms like ointments, creams, emulsions and gels is more preferred for the treatment of skin disease. Application of lipid based carriers in drug delivery in topical formulations has recently become one of the major approaches to improve drug permeation, safety, and effectiveness. These delivery systems include liposomes, ethosomes, transfersomes, Nanoemulsions (NEs), Solid Lipid Nanoparticles (SLNs) Nanostructured Lipid Carriers (NLCs) and micelles. Most of the liposomes and SLNs based products are in the market while some are under investigation. Transcutaneous delivery of therapeutics to the skin layer by novel lipid based carriers has enhanced topical therapy for the treatment of skin ailments. This article covers an overview of the lipid-based carriers for topical uses to alleviate skin diseases.

scholarly journals Transcutaneous penetration of a single-chain variable fragment (scFv) compared to a full-size antibody: potential tool for atopic dermatitis (AD) treatment

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Audrey Baylet ◽  
Raoul Vyumvuhore ◽  
Marine Laclaverie ◽  
Laëtitia Marchand ◽  
Carine Mainzer ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Ex Vivo ◽  
Topical Therapy ◽  
Human Keratinocytes ◽  
Raman Microspectroscopy ◽  
Interleukin 4 ◽  
Single Chain Variable Fragment ◽  
Single Chain ◽  
Administration Routes

AbstractCurrently, several biologics are used for the treatment of cutaneous pathologies such as atopic dermatitis (AD), psoriasis or skin cancers. The main administration routes are subcutaneous and intravenous injections. However, little is known about antibody penetration through the skin. The aim was to study the transcutaneous penetration of a reduced-size antibody as a single-chain variable fragment (scFv) compared to a whole antibody (Ab) and to determine its capacity to neutralize an inflammatory cytokine involved in AD such as human interleukin-4 (hIL-4). Transcutaneous penetration was evaluated by ex vivo studies on tape-stripped pig ear skin. ScFv and Ab visualization through the skin was measured by Raman microspectroscopy. In addition, hIL-4 neutralization was studied in vitro using HEK-Blue™ IL-4/IL-13 cells and normal human keratinocytes (NHKs). After 24 h of application, analysis by Raman microspectroscopy showed that scFv penetrated into the upper dermis while Ab remained on the stratum corneum. In addition, the anti-hIL4 scFv showed very efficient and dose-dependent hIL-4 neutralization. Thus, scFv penetrates through to the upper papillary dermis while Ab mostly remains on the surface, the anti-hIL4 scFv also neutralizes its target effectively suggesting its potential use as topical therapy for AD.

scholarly journals Transcutaneous penetration of a single-chain variable fragment (scFv) compared to a full-size antibody: potential tool for Atopic Dermatitis (AD) treatment

2021 ◽  
Author(s):  
Audrey Baylet ◽  
Raoul Vyumvuhore ◽  
Marine Laclaverie ◽  
Laëtitia Marchand ◽  
Carine Mainzer ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Ex Vivo ◽  
Topical Therapy ◽  
Human Keratinocytes ◽  
Raman Microspectroscopy ◽  
Poly I:C ◽  
Interleukin 4 ◽  
Single Chain Variable Fragment ◽  
Single Chain ◽  
Polycytidylic Acid

SummaryBackgroundCurrently, several biologics are used for the treatment of cutaneous pathologies such as atopic dermatitis (AD), psoriasis (PSO) or skin cancers. The main administration routes are subcutaneous and intravenous injections. However, little is known about antibody penetration through the skin.ObjectivesThe aim was to study the transcutaneous penetration of a reduced-size antibody as a single-chain variable fragment (scFv) compared to a whole antibody (Ab) and to determine its capacity to neutralize an inflammatory cytokine involved in AD such as human interleukin-4 (hIL-4).MethodsTranscutaneous penetration was evaluated by ex vivo studies on tape-stripped pig ear skin. Antibody visualization through the skin was measured by Raman microspectroscopy. In addition, hIL-4 neutralization was studied using two 2D models. First, embryonic alkaline phosphatase (SEAP) secretion by HEK-Blue™ IL-4/IL-13 cells, proportional to hIL-4 cells stimulation, was quantified by OD 620 nm measurement in presence or absence of an anti-hIL4 scFv or Ab. Then, normal human keratinocytes (NHKs) were stimulated with polyinosinic-polycytidylic acid (poly I:C) +/− hIL-4 and treated with anti-hIL4 scFv. Human Interleukin-8 (hIL-8) concentrations were determined in culture supernatants by ELISA.ResultsAfter 24h of application, analysis by Raman microspectroscopy showed that scFv penetrated into the upper dermis while Ab remained on the stratum corneum. In addition, the anti-hIL4 scFv showed better efficiency compared to Ab, with a neutralization percentage at 200 nM of 68% and 47%, respectively, in the HEK-Blue™ IL-4/IL-13 model. hIL-8 dosage in stimulated NHKs supernatants revealed that addition of scFv induced a dose-dependent hIL-4 neutralization.ConclusionsscFv penetrates through to the upper papillary dermis while Ab remains on the surface. The anti-hIL4 scFv neutralizes its target effectively in two 2D models suggesting its potential use as topical therapy for AD.

Supplementary therapy in canine atopic dermatitis

2019 ◽  
Vol 24 (8) ◽  
pp. 400-407
Author(s):  
Sue Paterson
Keyword(s):  
Fatty Acids ◽  
Atopic Dermatitis ◽  
Specific Immunotherapy ◽  
Essential Fatty Acids ◽  
Topical Therapy ◽  
Allergen Specific Immunotherapy ◽  
Canine Atopic Dermatitis ◽  
Adequate Control ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Therapy for canine atopic dermatitis can be described as foundation or supplementary. Foundation therapy, which refers to allergen-specific immunotherapy, ciclosporin, glucocorticoids, lokivetmab and oclacitinib, is needed in all but the mildest of cases of canine atopic dermatitis. Supplementary therapies include drugs such as antihistamines, essential fatty acids, topical therapy and other systemic anti-inflammatory drugs. While it is uncommon for any of these supplementary drugs to provide adequate control of many cases of canine atopic dermatitis, they can reduce the frequency of relapse and reduce the amount of foundation therapy that is required when used in combination with them.

scholarly journals Atopic Dermatitis: Drug Delivery (Management) and Approaches (Strategies) in Perspective

2018 ◽  
Vol 54 (02) ◽  
pp. 078-089
Author(s):  
Virendra N. Sehgal
Keyword(s):  
Drug Delivery ◽  
Atopic Dermatitis ◽  
Treatment Options ◽  
Calcineurin Inhibitors ◽  
Cutaneous Manifestations ◽  
Topical Calcineurin Inhibitors ◽  
Systemic Corticosteroids ◽  
Age Related ◽  
Management Approaches ◽  
Minor Criteria

ABSTRACTAge-related cutaneous manifestations are definitive pointer to the diagnosis of atopic dermatitis, the confirmation of which is solicited by 3 major and 3 minor criteria. Its unpredictable course is punctuated by exacerbations and remissions. Several treatment options, namely: 1st, 2nd and 3rd line are in vogue ever since. The 1st line envisages general measures, 2nd encompasses topical applications, while the 3rd take into account drug therapy comprising, systemic Corticosteroids, Cyclosporin, Azathioprine, Thymopentin, Interferon–therapy, Topical Calcineurin inhibitors: Tacrolimus and Pimecrolimus. The mode of action, their dosages and adverse drug reaction (ADR), in particular, have been focused in this paper with special attention to refresh their drug delivery (management) approaches (strategies) in perspective. An endeavor to focus attention to emerging etio-pathogenesis, and its application in the contemporary context has also been made.

The characteristic features of the topical therapy of atopic dermatitis: a modern interpretation

2015 ◽  
Vol 14 (6) ◽  
pp. 103
Author(s):  
O. V. Zhukova ◽  
L. S. Kruglova ◽  
R. I. Ptashinskiy ◽  
S. A. Masyukova
Keyword(s):  
Atopic Dermatitis ◽  
Topical Therapy ◽  
Characteristic Features

The Use of Therapeutic Nanoparticulate Systems for Treating Atopic Dermatitis

2017 ◽  
Vol 14 (1) ◽  
pp. 3-16 ◽  
Author(s):  
Yin-Ku Lin ◽  
Wei-Ling Chou ◽  
Pei-Wen Wang ◽  
Shih-Chun Yang ◽  
Jia-You Fang
Keyword(s):  
Drug Delivery ◽  
Atopic Dermatitis ◽  
Barrier Function ◽  
Polymeric Nanoparticles ◽  
Controlled Drug Release ◽  
Systemic Complications ◽  
Abnormal Immune Response ◽  
Skin Targeting ◽  
Inflammatory Drugs ◽  
Inflammatory Skin Disorder

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder involving defects in epidermal barrier function and abnormal immune response to environmental stimuli. Standard treatment of AD involves topical application of emollients and anti-inflammatory drugs such as corticosteroids. Objective: Because of the barrier function defects in AD skin, the topical drug delivery can lead to systemic drug absorption, thereby eliciting systemic complications. Nanoparticles as the carriers used for cutaneous drug delivery provide some benefits over conventional formulations, including enhanced stability, improved epithelium permeability and bioavailability, controlled drug release, skin targeting, and minimal side effects. In recent years, the concept of using nanocarriers as vehicles for drug delivery to manage AD has attracted increasing attention. Polymeric nanoparticles, lipid nanoparticles, and liposomes are the most extensively studied nanocarriers for the treatment of AD. In this review, we highlight the recent progress on the development of nanosystems for AD treatment. Method: We systematically introduce the concepts and amelioration mechanisms of the nanomedical techniques for AD treatment. Different AD animal models for evaluating the efficacy of the therapeutic nanoparticles are described herein. Results: The discrepancy of the nanoparticle skin absorption between healthy skin and AD skin is also discussed. Conclusion: This review aimed to summarize the evidence for the therapeutic advantages of nanoparticles over the conventional AD therapy.

Sign in / Sign up

Export Citation Format

Share Document